Related Experiment Video
Updated: May 19, 2026
10:24
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
Pediatric apheresis with a novel apheresis device with electronic interface control
Jan Sörensen1, Andrea Jarisch, Carmelo Smorta
1Department of Pediatrics, Division of Stem Cell Transplantation and Immunology, the German Red Cross Blood Service Baden-Württemberg-Hesse, and the Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt, Germany.
Transfusion
|August 14, 2012
Summary
Pediatric stem cell apheresis is challenging in children under 20kg. This study shows the Spectra Optia MNC v.3.0 device is safe and effective for collecting stem cells in infants and toddlers.
Area of Science:
- Pediatric Hematology
- Stem Cell Transplantation
- Apheresis Technology
Background:
- Autologous stem cell transplantation for pediatric cancers is rare, leading to limited experience in pediatric apheresis collections.
- Collecting stem cells from small children (<20 kg) presents unique challenges, including small blood volume, venous access difficulties, anticoagulant dose concerns, and product volume limitations.
Purpose of the Study:
- To evaluate the feasibility and safety of autologous stem cell apheresis in infants and toddlers using a novel leukapheresis device.
- To describe system features that facilitate successful apheresis outcomes in very small pediatric donors.
Main Methods:
- A series of autologous stem cell apheresis procedures were performed in infants and toddlers weighing 5.5 to 20 kg.
- The Spectra Optia MNC v.3.0 leukapheresis device was utilized, marking the first reported use for pediatric stem cell collections in this weight range.
Main Results:
- Apheresis procedures were uneventful and successful, achieving collection efficiencies (median CE2, 36%) comparable to adult patients.
- While stem cell extraction was efficient, a considerable platelet attrition rate (58%) was observed.
Conclusions:
- Stem cell apheresis using the Spectra Optia MNC v.3.0 is feasible and safe for very small pediatric donors.
- The procedure yields very small product volumes suitable for autologous transplantation in infants and toddlers.
